Generic Drug Labeling
Witnesses testified at a hearing on the Food and Drug Administration’s FDA’s proposal to have generic drug makers update their safety labels… read more
Witnesses testified at a hearing on the Food and Drug Administration’s FDA’s proposal to have generic drug makers update their safety labels as soon as the information becomes available. At the time of this hearing, generic brands could not update labels unless the original developer did so. Some lawmakers expressed concern that the rule change could create contradictory labels for the same medicine. FDA official in charge of drug evaluation and research Janet Woodcock testified the first panel. In a separate panel, the subcommittee also heard from the president of the Generic Pharmaceutical Association. close
People in this video
-
Michael Shumsky Attorney
-
Janet Woodcock M.D. Director U.S. Food and Drug Administration->Center for Drug Evaluation and Research
Hosting Organization
Related Video
-
Power Plant Regulations
Janet McCabe testified on the Environmental Protection Agency’s (EPA) proposed carbon emissions regulations for existing…
-
FDA Safety and Innovation Act, Part 1
Senior Food and Drug Administration (FDA) officials gave an update on the implementation of the 2012 FDA Safety and Inno…
-
FDA Safety and Innovation Act, Part 2
Senior Food and Drug Administration (FDA) officials gave an update on the implementation of the 2012 FDA Safety and Inno…
-
Labeling Genetically Modified Foods
Industry and legal experts testified at a hearing on the role genetic engineering plays in the U.S. food supply and the …